NFL BIOSCIENCES: PARTICIPATION IN THE HCWAINWRIGHT 1ST ANNUAL MENTAL HEALTH CONFERENCE


NFL BIOSCIENCES: PARTICIPATION IN THE HCWAINWRIGHT 1ST ANNUAL MENTAL HEALTH CONFERENCE

NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, announcement that Ignacio Faus, General Manager of NFL Biosciences was invited to present at the conference  » HCWAINWRIGHT 1ST ANNUAL MENTAL HEALTH CONFERENCE on June 27 and 28, 2022.

On this occasion, NFL Biosciences will have the opportunity to present its activities and its development strategy to American professional investors. Ignacio Faus will detail in particular the implementation of the Phase II/III clinical study of the drug candidate NFL-101 for smoking cessation started in January 2022 in France. He will also discuss the co-development agreement for drug candidate NFL-301 to reduce alcohol consumption and the extension of intellectual property with the registration of the second patent of NFL-101 in the United States, China and in South Korea.

About NFL Biosciences

NFL Biosciences is a biopharmaceutical company based in the Montpellier region that develops botanical drug candidates for the treatment of addictions. NFL Biosciences aims to bring new therapeutic, natural, safer and more effective solutions to the entire world population, without forgetting countries with low or average income levels. Its most advanced product, called NFL-101, is a standardized, nicotine-free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who wish to quit a natural, safe, simplified and personalized administration alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders.

NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). The company is qualified as an “Innovative Company” eligible for FCPI investment. More information on www.nflbiosciences.com

contacts

Bruno Lafont – info@nflbiosciences.com – 04 11 93 76 67 Calyptus Agency – nflbio@calyptus.net – 01 53 65 68 68

  • 20220624_NFLBioscience_HCWrainwrightConference_EN

Laisser un commentaire